INNOVATIVE DRUG DAILY· NO.005本期速览中文
:本期主线为"一收一扩"——强生以最高约 33.25 亿美元收购信达生物合作伙伴 Ollin(OLN324,VEGF/Ang2 双抗,强生首付 22 亿美元+黑石 7.5 亿美元三期注资),礼来 15 亿美元收购 Calytrix;FDA 同日批准罗氏 Wilserdly(giredestrant,首个下一代口服 SERD)与阿斯利康 Klygefa(gefurulimab,全球首款每周一次皮下 C5 纳米抗体)。国内方面,2026 版医保双目录正式文件印发并公布官方解读,第十二批国采江西率先执行、多地陆续铺开;依沃西美国 CRL 后 48 小时内,一线胆道癌适应症获 CDE 受理——"同款药、两种监管叙事"。English
: This issue is headlined by J&J's acquisition of Innovent-partnered Ollin Biosciences (OLN324, VEGF/Ang2 bispecific; $2.2B upfront plus up to ~$1.125B milestones, with Blackstone funding $750M of Phase 3) and Lilly's $1.5B buyout of Calytrix. FDA cleared Roche's Wilserdly (giredestrant, first next-generation oral SERD) and AstraZeneca's Klygefa (gefurulimab, first weekly subcutaneous C5 nanobody) on the same day. In China, the official 2026 dual reimbursement catalogs were formally issued with detailed guidance, the 12th national VBP rollout began in Jiangxi, and — 48 hours after ivonescimab's US CRL — the biliary tract cancer first-line sNDA was accepted by CDE: one drug, two regulatory narratives.一、BD 交易与授权合作1. 强生 22 亿美元收购 Ollin Biosciences,黑石 7.5 亿美元包干 III 期(本期头条)中文
:11 月 16 日晚,强生宣布与 Ollin Biosciences 达成最终收购协议——首付 22 亿美元,另设最高约 11.25 亿美元监管与商业里程碑,总对价最高约 33.25 亿美元(约人民币 221.6 亿元),预计 2026 年底前交割。核心资产 OLN324 为 VEGF/Ang2 双特异性抗体(minibody 构型),全球 III 期在即,拟用于 wAMD 与 DME。该分子由信达生物研发(内部代号 IBI324),经 NewCo 模式授权给 Ollin,信达保留大中华区权益并持有 Ollin 股权。强生同时与黑石生命科学签订独立开发资金协议:黑石将分多年向强生支付合计 7.5 亿美元全额支持 OLN324 的 III 期开发,换取特定里程碑付款与个位数版税(不计入收购对价)。Ib 期 JADE 头对头研究(164 例)显示:DME 患者 OLN324 组第 1 周 CST 降幅较罗氏法瑞西单抗高约 75%(-79μm vs -45μm),第 12 周 -180μm vs -121μm,DME 消失率(CST<325μm)约 90% vs 57%。English
: On Nov 16, Johnson & Johnson announced a definitive agreement to acquire Ollin Biosciences for a $2.2B upfront payment plus up to ~$1.125B in regulatory and commercial milestones (total potential value ~$3.325B), expected to close before the end of 2026. The prize is OLN324, a Phase 3-ready VEGF/Ang2 bispecific antibody in a compact minibody format for wet AMD and DME, originally developed by Innovent (IBI324) and out-licensed to Ollin via a NewCo structure, with Innovent retaining Greater China rights and an equity stake. Alongside the acquisition, J&J signed a separate development-funding agreement with Blackstone Life Sciences: Blackstone will pay J&J a total of $750M over several years to fully fund OLN324's Phase 3 program in exchange for milestone payments and single-digit royalties (not counted in the deal value). Final JADE Phase Ib head-to-head data (164 patients) showed deeper retinal drying vs Roche's faricimab in DME — CST reduction of -79μm vs -45μm at Week 1 (~75% greater) and -180μm vs -121μm at Week 12, with ~90% vs 57% achieving DME resolution.2. 礼来 15 亿美元收购 Calytrix,延续"小而早"M&A 连击中文
:11 月 16 日,礼来宣布以最高 15 亿美元收购血液肿瘤公司 Calytrix Bio,核心为骨髓纤维化与原发性血小板增多症相关项目。这是继近期多笔私有公司收购后,礼来在早期资产并购上的又一连击——BioPharma Dive 的 M&A 追踪显示,2026 年行业并购活动中私有公司收购已占多数,礼来与强生周一(11-16)同日添砖。English
: On Nov 16, Lilly added to its buyout streak with a deal of up to $1.5B for Calytrix Bio, centered on programs in myelofibrosis and essential thrombocythemia. Per BioPharma Dive's M&A tracker, private-company acquisitions account for the majority of 2026 dealmaking, with Lilly and J&J both adding deals on Monday.3. Biogen × TRIMTECH:4.11 亿美元押注 TRIM21 蛋白降解平台中文
:Biogen 与英国 TRIMTECH Therapeutics 达成战略合作、选择权与许可协议:首付及近期研究里程碑至多 3,200 万美元,总潜在金额至多 4.11 亿美元外加版税。TRIMTECH 基于 E3 连接酶 TRIM21 清除致病蛋白聚集体,代表技术为双特异性嵌合分子 TRIMTAC 与分子胶促进剂 TRIMGLUE,是 PROTAC 之外的另一条降解路线;拟布局亨廷顿病、阿尔茨海默病与帕金森病。该公司 2023 年创立,今年 4,700 万美元种子轮获强生、礼来、辉瑞参与。English
: Biogen entered a strategic research collaboration, option, and license agreement with UK-based TRIMTECH Therapeutics worth up to $411M, including up to $32M in upfront and near-term research milestone payments plus royalties. TRIMTECH's platform, built on the E3 ligase TRIM21 to clear disease-causing protein aggregates (bispecific TRIMTAC and molecular-glue facilitator TRIMGLUE), offers an alternative to bivalent PROTAC degraders, targeting Huntington's, Alzheimer's, and Parkinson's disease. Founded in 2023, the company raised a $47M seed round backed by J&J, Eli Lilly, and Pfizer.4. Seawolf Therapeutics:1 亿美元融资 + 赛诺菲最高 12 亿美元合作中文
:Versant 孵化的 DNA 药物公司 Seawolf Therapeutics 同步披露两件事:由 Versant、MPM BioImpact、礼来与诺华风投等重磅投资人支持的 1 亿美元融资,以及与赛诺菲总金额至多 12 亿美元的合作,开发可重复给药的非病毒 DNA 药物(redosable DNA medicines)。English
: Versant-incubated DNA therapeutics developer Seawolf Therapeutics surfaced with a $100M financing backed by Versant, MPM BioImpact, Eli Lilly, and Novartis' venture arm, together with a partnership with Sanofi worth up to $1.2B for its redosable, nonviral DNA medicines platform.5. 国内及其他交易速览中文
:药康生物 11-17 披露拟收购佰麦生物 80% 股权(安评 CRO 垂直整合);Leo Pharma 因市况不佳推迟 2026 年 IPO 申报(彭博/Fierce Pharma 11-16);欧洲风投 Sofinnova 完成 7.25 亿欧元 crossover 基金二期募集(11-16)。English
: KangKangBio (药康生物) disclosed plans to acquire 80% of CRO Baomai Biotech (Nov 17); Leo Pharma is delaying its planned 2026 IPO filing amid unfavorable markets (Bloomberg via Fierce Pharma, Nov 16); Europe's Sofinnova banked a €725M crossover fund (Nov 16). 本期 BD 交易一览表
交易
类型
金额
关键资产/领域
强生 × Ollin Biosciences
收购
$22 亿首付 / 总额最高 ~$33.25 亿
OLN324(VEGF/Ang2 双抗,信达 IBI324 出海)wAMD/DME
强生 × 黑石生命科学
开发资金
$7.5 亿(不计入对价)
OLN324 III 期全额注资,换取里程碑+个位数版税
礼来 × Calytrix Bio
收购
至多 $15 亿
骨髓纤维化/原发性血小板增多症
Biogen × TRIMTECH
合作+许可
$3,200 万首付级 / 总额 $4.11 亿
TRIM21 蛋白降解(TRIMTAC/TRIMGLUE),神经退行性疾病
赛诺菲 × Seawolf
合作
至多 $12 亿
可重复给药非病毒 DNA 药物平台
药康生物 × 佰麦生物
收购(国内)
80% 股权
安评 CRO 垂直整合二、药企信息与战略动向1. 强生加码眼科:从"器械隐形眼镜"补齐"视网膜药物"短板中文
:强生眼科长期以隐形眼镜、白内障/屈光手术设备与耗材为主,视网膜药物布局与其体量不匹配。本次收购 Ollin 属"直接买 III 期资产"打法:既能与罗氏 Vabysmo 正面对标,又通过黑石注资把多年研发现金支出转为共担风险结构。券商分析指出,交易实质是三层安排——强生拿资产、黑石担费用、信达经股权与经济权益分享升值。English
: J&J's ophthalmology franchise has long leaned on contact lenses and cataract/refractive surgical devices, with limited retinal pharma presence. Buying Ollin is a "buy-Phase-3-asset" play that positions OLN324 directly against Roche's Vabysmo, while the Blackstone funding converts multi-year R&D cash outlays into a shared-risk structure. Analysts frame the deal as a three-layer arrangement: J&J takes the asset, Blackstone carries the costs, and Innovent shares upside via equity and economic rights.2. IQVIA:九成新药不盈利,回本门槛升至 120 亿美元中文
:IQVIA 11-16 发布报告:2016—2020 年上市的新药约九成无法实现正回报,正回报所需销售额中位数升至近 120 亿美元(1990 年代初上市药品仅需约 14 亿美元),研发成本高企与支付压力并存。这一数据为当前"MNC 收缩+聚焦确定性"的行业行为提供了注脚。English
: An IQVIA report (Nov 16) finds roughly 9 in 10 medicines launched between 2016 and 2020 fail to generate a positive return; drugs now need nearly $12B in sales to break even, up from just $1.4B for launches in the early 1990s. The finding contextualizes Big Pharma's tightening focus on late-stage certainty.3. 裁员与重组:AZ、Calidi、Tempest;BMS 研发架构整合中文
:BioSpace 裁员追踪(11-16 更新):阿斯利康(含此前报道的美国销售岗)、Calidi、Tempest 均有显著裁员动作。此前 BioPharma Dive 报道,BMS 研究负责人 Robert Plenge 将离职,公司合并研发部门以加速开发并拥抱新技术,Cristian Massacesi 接棒——研发架构"整合提速"成为 MNC 共性动作。English
: BioSpace's Layoff Tracker (updated Nov 16) logs significant workforce cuts at AstraZeneca, Calidi, and Tempest. Bristol Myers Squibb's research chief Robert Plenge is departing as the company merges its R&D organization to speed development and capitalize on new technologies, with Cristian Massacesi taking over — consolidation of research structures is now a cross-industry pattern.4. 国内企业动态中文
:药明巨诺 11-15 晚公告,瑞基奥仑赛医保支付标准 28.86 万元(进保前定价 129 万元,降幅约 77.6%),管理层否认"赔本赚吆喝",称国产替代与规模效应将推动单位生产成本持续下降超 65%,"在有利润基础的价格上打开放量空间";公司成为首个进基本医保的 CAR-T。银河证券 11-17 研报指出 TCE 交易爆发、正成为继双抗/ADC 之后新的 BD 热点。同仁堂左归丸获加拿大三类产品许可证(11-16,尚需生产质量体系认证)。English
: JW Therapeutics announced (Nov 15) that relmacabtagene's NHSA-negotiated price is ¥288,600 (a ~77.6% cut from the pre-listing ¥1.29M); management rejected the "loss-leader" narrative, saying domestic substitution and scale effects will cut unit production costs by over 65%, "opening volume at a profitable price" — the first CAR-T in China's national basic insurance. Galaxy Securities (Nov 17) flags T-cell engagers as the next BD hotspot after bispecifics and ADCs. Tong Ren Tang's Zuogui Wan secured a Canadian Class III product license (Nov 16).5. 市场行情(11-16/11-17)中文
:康方生物依沃西 CRL 后首个交易日(11-16)盘中一度大跌超 30%;11-17 港股创新药延续调整,康方生物收跌 22.11%,同源康 -9.53%、歌礼 -8.95%、复宏汉霖 -6.82%、君实 -5.28%、再鼎 -5.24%、荣昌 -4.80%、泰格 -4.18%,恒生生物科技指数盘中跌近 2%。A 股 11-17 三大指数集体下跌,中证创新药产业指数 -0.77%,生物医药板块 -1.40%,复星医药 A 股 -6.81% 居跌幅前列(创新药 ETF 交投活跃,海通国际建议关注回调后的优质龙头)。English
: In the first HK session after ivonescimab's CRL (Nov 16), Akeso fell as much as 30%+ intraday; on Nov 17 innovative-drug names extended losses — Akeso -22.11%, cremophor players and others down:同源康 -9.53%, Ascletis -8.95, Henlius -6.82%, Junshi -5.28%, Zai Lab -5.24%, Rongchang -4.80%, Tigermed -4.18%, with the Hang Seng Biotech index down nearly 2% intraday. On the A-share side (Nov 17), the CSI Innovative Drug index fell 0.77% and the pharma-biotech sector -1.40%, with Fosun Pharma -6.81% among the worst; innovative-drug ETFs stayed active.三、全球政策与监管1. 医保双目录正式文件印发,官方解读与落地时间表明确中文
:国家医保局、人社部 11-14 正式印发《国家基本医疗保险、生育保险和工伤保险药品目录(2026年)》及《商业健康保险创新药品目录(2026年)》。官方口径补全:新增 107 种(1 类创新药 51 个,创新高)、调出 34 种,净增 78 个编号、总数 3,331(西药 1,935/中成药 1,396),中药饮片 885;商保目录新增 12 种、总数 28,2 个 2025 商保品种转入基本医保。落地时间表:2027-01-01 执行、12 月底前完成挂网、医疗机构原则上 2027 年 2 月底前召开药事会("预进院"配套)。官方解读强调"预申报"机制——百利天恒伦康依隆妥(全球首个双抗 ADC)上市首年即入保,复宏汉霖斯鲁利单抗获批当年入保;CAR-T 与血友病非因子药物首次纳入基本医保。025/027 期已覆盖发布会头条,本期为正式文件与配套细则增量。English
: NHSA and the Ministry of Human Resources formally issued the 2026 national reimbursement drug list and the commercial health insurance innovative drug list on Nov 14: 107 additions (a record 51 class-1 innovative drugs), 34 deletions, a net +78 entries bringing the total to 3,331 (1,935 western drugs, 1,396 TCM); the commercial list adds 12 drugs to 28, with two 2025 commercial-list items crossing over into basic insurance. Implementation: effective Jan 1, 2027, listing completion by end-December, and hospital pharmacy committees to convene by end-February 2027 under the "pre-admission" mechanism. Officials highlighted the first-time "pre-application" channel — Baili Tianheng's dual-ADC entered insurance in its launch year, as did Henlius' serplulimab — plus the historic inclusion of CAR-T and non-factor hemophilia drugs. (Headline figures previously covered in Issues 025/027.)2. 第十二批国采进入执行期:江西率先落地,多地差异化推进中文
:11-16 零时起江西率先执行第十二批国采(65 品种/327 家企业 521 个产品中选,迄今规模最大一批)。各地节奏:湖北 11-20、安徽 11-26、重庆/福建 11-27、北京 11-28、河南/甘肃/贵州/黑龙江/海南 11-30;福建 12-4 起同步执行差别化医保支付标准。多地明确"可适量采购非中选产品、避免一刀切停用",按适应症报量的沙库巴曲缬沙坦仅考核约定采购量;诺华 11-16 表示沙库巴曲缬沙坦钠片将陆续启动落地执行。English
: The 12th national VBP round has entered implementation: Jiangxi began executing on Nov 16 (65 products; 521 items from 327 companies — the largest round ever). Other provinces follow a staggered calendar — Hubei Nov 20, Anhui Nov 26, Chongqing/Fujian Nov 27, Beijing Nov 28, Henan/Gansu/Guizhou/Heilongjiang/Hainan Nov 30, with Fujian applying differentiated reimbursement from Dec 4. Multiple provinces explicitly permit "measured procurement of non-winning products, avoiding one-size-fits-all discontinuation"; sacubitril/valsartan (indication-based bidding) is assessed on contracted volumes only. Novartis confirmed (Nov 16) its Entresto tablets will roll out under the VBP terms.3. FDA 人手短缺:逾千岗位空缺,审评周期承压中文
:BioPharma Dive 报道,FDA 目前有超过 1,000 个空缺岗位,去年大规模人员流失后的恢复缓慢, staffing 短板已开始影响药企审评沟通与时间表——对 2026—2027 年密集到期的 PDUFA 决议(包括 11-14 IGALMI 至今未公布)是潜在背景变量。English
: BioPharma Dive reports the FDA has over 1,000 open positions and is still recovering from last year's mass staff exodus; the shortfall is starting to hit sponsors' review timelines — a background variable for the dense 2026–27 PDUFA calendar (note: Teva's IGALMI decision, due Nov 14, has yet to appear).4. 其他政策动态中文
:CTAD 2026(波士顿,11-16—19)开幕,阿尔茨海默病领域"超越淀粉样蛋白"成为主题,Biogen/BMS/罗氏等携新数据参会(ProMIS PMN310 六个月中期数据海报);海关总署发布防止埃博拉疫情传入公告(11-16);BIO-Europe 会场,加拿大借美国政策波动向欧洲企业"招手", positioning 为更稳定的研发合作目的地。English
: CTAD 2026 opens in Boston (Nov 16–19) with the Alzheimer's field "looking beyond amyloid" — Biogen, BMS, and Roche bring new data (ProMIS' PMN310 six-month interim poster included). China's customs authority issued an Ebola entry-prevention announcement (Nov 16). At BIO-Europe, Canada is courting European partners amid US policy instability, positioning itself as a steadier R&D destination.四、临床进展与监管批准1. FDA 批准:Wilserdly(giredestrant)与 Klygefa(gefurulimab)同日落地中文
:罗氏/基因泰克 11-16 宣布 FDA 批准 Wilserdly(giredestrant)联合依维莫司,用于 ER+/HER2-/ESR1 突变晚期乳腺癌(既往内分泌治疗进展),为首个获批的下一代口服 SERD 组合——evERA III 期显示 PFS 风险降低 62%(HR 0.38,p<0.0001,NEJM 同步);辅助治疗递交获优先审评,PDUFA 2026-11-30,若获批将是 20 多年来首个新的辅助内分泌治疗。同日,阿斯利康/Alexion 宣布 Klygefa(gefurulimab)欧盟与美国同日获批用于抗 AChR+ 全身型重症肌无力——全球首款双靶点 C5 纳米抗体(C5+白蛋白结合延半衰期),每周一次皮下自动注射;PREVAIL III(260 例)显示 26 周 MG-ADL 改善 4.2 vs 2.6 分,黑框警告为脑膜炎奈瑟菌感染(REMS 管理);该药正基于 PREVAIL 在中国审评中。另:罗氏 11-16 官宣 Gazyva(奥妥珠单抗)获批原发性膜性肾病(MAJESTY:104 周完全缓解率 36.1% vs 他克莫司 5.7%,FDA 官网 11-13 更新)。English
: Roche/Genentech announced FDA approval of Wilserdly (giredestrant) plus everolimus for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer — the first approved next-generation all-oral SERD combination — after the Phase 3 evERA trial cut the risk of progression or death by 62% (HR 0.38; p<0.0001; NEJM). The adjuvant filing is under Priority Review with a PDUFA of Nov 30, which would make it the first new adjuvant endocrine therapy in 20+ years. The same day, AstraZeneca/Alexion won simultaneous EU and US approvals for Klygefa (gefurulimab) in AChR-antibody-positive generalized myasthenia gravis — the first dual-binding C5 nanobody (C5 + albumin binding for half-life extension) with once-weekly subcutaneous autoinjection; PREVAIL III (n=260) showed a 4.2- vs 2.6-point MG-ADL improvement at Week 26, with a boxed warning for meningococcal infection (REMS required). China review is ongoing. Separately, Roche confirmed (Nov 16) FDA approval of Gazyva (obinutuzumab) in primary membranous nephropathy (MAJESTY: 36.1% vs 5.7% complete remission at 104 weeks; FDA site updated Nov 13).2. FDA 决议补充:aficamten 标签更新获批、IGALMI 仍未公布中文
:Cytokinetics 宣布 FDA 批准 MYQORZO(aficamten)sNDA,将 MAPLE-HCM 头对头数据写入美国说明书(PDUFA 11-14 到期落地),成为唯一在说明书中载有"与美托洛尔头对头比较"数据的心肌肌球蛋白抑制剂(单药 pVO2 多改善 2.3 mL/kg/min);非梗阻型 HCM(ACACIA-HCM)补充申请拟 2026Q4 递交。Teva 的 IGALMI(右美托咪定舌下膜,居家自用标签扩展)PDUFA 11-14 已过但仍无决议——BioXcel 破产重整中资产交接或影响审评节奏。English
: Cytokinetics said FDA approved an sNDA adding MAPLE-HCM head-to-head data to the US label of MYQORZO (aficamten) — the PDUFA due Nov 14 has landed — making it the only cardiac myosin inhibitor with metoprolol-comparative data in its label (2.3 mL/kg/min greater single-agent pVO2 improvement); the non-obstructive HCM filing follows in Q4. Teva's IGALMI (dexmedetomidine sublingual film, at-home label expansion) remains undecided past its Nov 14 PDUFA, possibly slowed by the BioXcel bankruptcy asset handover.3. 临床数据:CG Oncology 膀胱癌 III 期"例外级"成功中文
:CG Oncology 公布 PIVOT-006 III 期:cretostimogene(溶瘤病毒 CGB 型)用于中危 Ta 型(≤3cm)非肌层浸润性膀胱癌 TURBT 术后辅助治疗,复发风险较对照组降低 68%(HR 0.32,95%CI 0.23–0.45,p<0.0001,367 例、约 90 个中心);公司计划 2027Q2 递交 BLA,顶线数据 12-2 泌尿肿瘤学会年会公布。Lexeo LX2020(PKP2 致心律失常性心肌病基因治疗)I/II 期中期:高剂量组 NSVT 平均减少 80%、PVC 减少 44%,FDA 认可 NSVT 作为加速批准的替代终点。Aclaris bosakitug(抗 TSLP?)II 期 ADMIRATION 特应性皮炎未达主要与次要终点。English
: CG Oncology reported "exceptional" Phase 3 PIVOT-006 results: cretostimogene reduced recurrence risk by 68% (HR 0.32; 95% CI 0.23–0.45; p<0.0001) vs control as adjuvant therapy in intermediate-risk Ta (≤3 cm) non-muscle-invasive bladder cancer after resection (367 patients, ~90 sites); a BLA is planned for Q2 2027 with topline at the Society of Urologic Oncology meeting Dec 2. Lexeo's LX2020 gene therapy showed interim Phase I/II reductions of 80% in NSVT and 44% in PVCs (high-dose cohorts) in PKP2 arrhythmogenic cardiomyopathy, with FDA open to NSVT as an accelerated-approval surrogate. Aclaris' Phase 2 ADMIRATION trial of bosakitug missed primary and secondary endpoints in atopic dermatitis.4. Helus HLP003 疗效强劲但严重不良事件蒙阴影;ObesityWeek 续报中文
:Helus Pharma 11-16 公布 HLP003(迷幻类,辅助治疗重度抑郁)III 期 APPROACH 顶线:疗效数据强劲,但严重不良事件拖累,股价当日大跌;迷幻药监管风险再被定价。ObesityWeek 续报:诺和 CagriSema 低剂量组减重亦超 20%(026 期已收录 REDEFINE 9 主数据,本条为持续传播);Wave Life Sciences WVE-007(siRNA 减重)按体成分分层显示基线 BMI/体脂越高效果越显著,Rodman & Renshaw 建议以体成分设计后续试验;Biomea BMF-650(口服小分子 GLP-1)I 期、Veru enobosarm(≥65 岁司美联合人群躯体功能)post hoc 同日海报。English
: Helus Pharma reported Phase 3 APPROACH topline (Nov 16) for HLP003, a psychedelic adjunct in major depression: robust efficacy marred by serious adverse events, sending shares sharply lower. ObesityWeek continued: Novo showed CagriSema's lower doses still drive >20% weight loss (headline REDEFINE 9 data covered in Issue 026); Wave Life Sciences' WVE-007 (siRNA) shows stronger effects at higher baseline BMI/body fat, supporting body-composition-based trial design; Biomea (oral GLP-1 BMF-650 Ph1) and Veru (enobosarm post hoc in ≥65s on GLP-1s) also presented.5. 国内审批与受理(NMPA/CDE,11-16/17)中文
:批准——以岭药业半夏白术天麻汤颗粒(中药 3.1 类经典名方,公司首个经典名方品种,公告 11-17);恩华药业盐酸羟考酮缓释片(防滥用屏障技术,补齐 10mg 小规格);羚锐制药氟比洛芬凝胶贴膏(化药 4 类,2025 年三大终端销售约 41 亿元);中国医药佩玛贝特原料药。IND 获批——复宏汉霖 HLX105(PD-1 融合 IL-2 变体抗体融合蛋白)、康希诺五组分百白破联合疫苗 Td5cp、先声 SIM0712(一药覆盖 5 个 2 型炎症适应症)、上海莱士蛋白 C(国内首创罕见病血液制品)、亿腾嘉和 GB268(PD-1/CTLA-4/VEGF 三特异抗体,NSCLC Ib/II 期 + BTC II/III 期两项)。受理——依沃西单抗一线胆道癌 sNDA(受理号 CXSS2600188,11-16,OS 14.9 vs 12.1 月),与美国 CRL 形成"48 小时两种监管叙事"。海外通道——歌礼 ASC10 猴痘适应症获 FDA IND 批准(猴痘迄今无获批口服抗病毒);北海康成 CAN106(C5 单抗,gMG)获 FDA 孤儿药资格。仿制药——Apotex 于美国上市阿昔替尼片(INLYTA 首仿,11-16)。English
: NMPA approvals — Yiling's Banxia Baizhu Tianma granules (TCM 3.1 classical-formula category, its first); Enhua's abuse-deterrent oxycodone ER tablets (10 mg strength added); Lingrui's flurbiprofen cataplasms (chem. class 4); China National Pharmaceutical's pemafibrate API. IND clearances — Henlius HLX105 (PD-1×IL-2 variant fusion), CanSino's five-component pertussis vaccine Td5cp, Simcere SIM0712 (five type-2 inflammation indications), Shanghai RAAS Protein C, and Eddingpharm/Jaker's GB268 (PD-1/CTLA-4/VEGF trispecific; NSCLC Ib/II and BTC II/III). CDE accepted ivonescimab's first-line biliary tract cancer sNDA (No. CXSS2600188, Nov 16; OS 14.9 vs 12.1 months) — two regulatory narratives in 48 hours. US-track — Ascletis' ASC10 won FDA IND for mpox (no approved oral antiviral exists); CanBridge/北海康成's CAN106 (C5 mAb for gMG) received FDA orphan-drug designation. Generics — Apotex launched the first US axitinib (Inlyta) generic (Nov 16).6. 本期关键临床/批准速览表
事件
公司
结论/状态
关键数据
Wilserdly (giredestrant) 获批
罗氏
FDA 批准(晚期)/辅助 PDUFA 11-30
evERA PFS HR 0.38,风险降 62%
Klygefa (gefurulimab) 获批
AZ/Alexion
欧盟+美国同日获批
MG-ADL 4.2 vs 2.6;每周一次皮下
MYQORZO 标签更新
Cytokinetics
sNDA 获批(PDUFA 11-14)
MAPLE-HCM 头对头入标签
PIVOT-006 III 期
CG Oncology
达主要终点
复发风险 -68%(HR 0.32)
APPROACH III 期顶线
Helus
疗效强/SAE 拖累
迷幻类辅助 MDD
依沃西一线胆道癌受理
康方/CDE
受理(11-16)
OS 14.9 vs 12.1 月
ADMIRATION II 期
Aclaris
未达终点
特应性皮炎五、常青主题线索PD-1/VEGF 出海与 OS 终点
(027 期起):BioSpace 11-16 分析指出,FDA 对依沃西的拒绝给整个 PD-1×VEGF 类上了"必须建立总生存期获益"的一课——Summit 另有多个依赖 HARMONi 系列 OS 数据的适应症在审,约 45.6 亿美元里程碑兑现节奏存疑;国内同类三抗(如亿腾嘉和 GB268)推进路径需重新校准终点设计。CAR-T 进基本医保
(025 期起):药明巨诺首例落地(28.86 万支付标准、成本降 65% 承诺),"商保转医保"通道首次走通,后续关注其他 CAR-T 品种跟进与实际放量数据。TCE 交易热
(016 期 TCE 三抗起):银河证券 11-17 报告将 TCE 列为继双抗/ADC 后新 BD 热点;本周 Biogen×TRIMTECH(降解平台)、强生×Ollin(眼科双抗)显示 MNC 平台型布局持续。减重赛道(ObesityWeek 2026,11-14—17)
:CagriSema 低剂量 >20% 减重、WVE-007 体成分设计、口服小分子 GLP-1(BMF-650)接力,关注 11-17/18 剩余口头场。第十二批国采执行
(017 期起):江西 11-16 首执落地,全国执行至 11-30 完成,"避免一刀切"成多地政策口径。PDUFA 日历
:11-22 deramiocel(Capricor,DMD)/molgramostim(Savara,aPAP);11-25 venglustat;11-27 neladalkib;11-30 povetacicept(Vertex)/giredestrant 辅助治疗 + GLOBE 国际参考定价规则生效。六、核验说明与数据口径中文
:① J&J×Ollin 金额以强生官网与财联社(11-17)为准:首付 22 亿 + 里程碑约 11.25 亿;黑石 7.5 亿美元为独立开发资金协议、不计入对价。② 依沃西 11-16 盘中跌幅(-30%+)来自每经医药早参口径,11-17 收盘 -22.11% 来自东方财富港股收评口径,两日口径不同已分别标注。③ 027 期已收录的 Gazyva 膜性肾病批准,本期仅补罗氏 11-16 官宣口径。④ 双目录头条数据(107/51/3331/28)以国家医保局官网与新华社/央广报道为准。⑤ 生物医药板块行情以 2026-11-17 15:00 收盘数据为准。English
: Cross-checked against J&J/Roche/AZ press releases, NHSA releases, BioSpace, BioPharma Dive, and Fierce Pharma list pages; intraday vs close prices labeled by session; previously covered items (Issues 024–027) are marked as incremental only.